CN100431553C - Composition for improving obstacle under pharynx - Google Patents
Composition for improving obstacle under pharynx Download PDFInfo
- Publication number
- CN100431553C CN100431553C CNB031482597A CN03148259A CN100431553C CN 100431553 C CN100431553 C CN 100431553C CN B031482597 A CNB031482597 A CN B031482597A CN 03148259 A CN03148259 A CN 03148259A CN 100431553 C CN100431553 C CN 100431553C
- Authority
- CN
- China
- Prior art keywords
- compositions
- inhibitory action
- obstacle
- secretion facilitation
- substance decomposition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition for improving swallowing reflex failure characterized by comprising a substance P secretion promoter with an angiotensin convertase inhibitor or a substance P decomposition inhibitor and/or a dopamine secretion promoter; and a food and a drug for improving swallowing reflex failure which contain this composition.
Description
Technical field
The present invention relates to a kind of improvement and swallow the obstacle compositions, in particular to a kind of improvement that in P material secretion facilitation material, has cooperated ace inhibiting effect material or P substance decomposition inhibitory action material and/or dopamine secretion facilitation material to form swallow obstacle with compositions, reach the improvement that constitutes by said composition and swallow food or the pharmaceuticals that obstacle is used.
Background technology
What is called is swallowed obstacle, is at preventing that by cough saliva or food are strayed in the bronchus or assorted bacterium is invaded obstacle the defense function of intrabronchial living organism.Because this obstacle is likely and causes that the more weak person at advanced age of resistance suffers from fatal pneumonia, so prevent to swallow obstacle directly and the prevention associated of illness such as pneumonia.
As everyone knows, swallowing obstacle produces along with the minimizing of the growing amount of intravital P material that is caused by central nervous system disorder and dopamine.It is documented, can promote the secretion of P material as the capsaicin of Fructus Capsici pungency component, along with can improving, the rising of its concentration swallows reflection function (non-patent literature 1), in addition, also there is document to point out that intravenous injection dopamine precursor material levodopa can improve consciously and swallows obstacle (non-patent literature 2).
And; also have document to point out in recent years; (below be referred to as ACE) not only has the effect that the angiotensin i-converting of making is II because angiotensin converting enzyme; but also participated in the decomposition of P material; therefore; ACE suppresses activity and has hindered the effect of P substance decomposition, consequently makes the concentration normalization of P material, swallows obstacle (non-patent literature 3) thereby improve.
[non-patent literature 1]
Kbihara?T.，“Lancet”，1993，Vol.341，P.432
[non-patent literature 2]
Kobayashi?H.，“Lancet”，1996，Vol.348，P.1320-1321
[non-patent literature 3]
The wooden English loyalty of assistant assistant, " Japanese doctor understands magazine ", calendar year 2001,125:973-977
Swallow obstacle though use these materials to improve as everyone knows respectively separately, the combination role of these materials does not also have report.
Summary of the invention
Under this situation, the inventor finds, in P material secretion facilitation material, be used in combination ACE inhibitory action material or P substance decomposition inhibitory action material and/or dopamine secretion facilitation material, can improve more significantly during than these materials of independent use and swallow obstacle.
Therefore, the invention provides a kind of improvement that in P material secretion facilitation material, has cooperated ACE inhibitory action material or P substance decomposition inhibitory action material and/or dopamine secretion facilitation material to form swallow obstacle with compositions, reach the improvement that constitutes by said composition and swallow food or the pharmaceuticals that obstacle is used.
The specific embodiment
In the present invention, there is no particular limitation for P material secretion facilitation material, but can enumerate capsaicin as particularly preferred material.
ACE inhibitory action material or P substance decomposition inhibitory action material, can use the material that suppresses the P substance decomposition, particularly, can enumerate as non-medicament as medicament, Lac regis apis and enzyme analyte thereof, wooden fish enzymic digestion thing, sardine enzymic digestion thing, the acid breasts of Calpis etc. such as her Mi Puli (imidapril) of depressor, cilazapril, captopril, alacepril, delapril hydrochloride.Wherein, preferred especially Lac regis apis and enzyme analyte thereof.
In addition,, can enumerate theanine as the delicious composition of green tea, amantadine etc., be preferably theanine especially as dopamine secretion facilitation material.
When compositions of the present invention, by P material secretion facilitation material and ACE inhibitory action material or P substance decomposition inhibitory action material is formed or is made up of or when being secreted facilitation material, ACE inhibitory action material or P substance decomposition inhibitory action material and dopamine and secreted the facilitation material and all constitute by the P material P material secretion facilitation material and dopamine secretion facilitation material, no matter which kind of situation wherein, dose once can use with respect to 1.5 * 10 of P material secretion facilitation material
-4～15 μ g, ACE inhibitory action material or P substance decomposition inhibitory action material are 1.0 * 10
-3～500mg and dopamine secretion facilitation material are 0.5～500mg.
As the compositions of the present invention that in P material secretion facilitation material, has cooperated ACE inhibitory action material or P substance decomposition inhibitory action material and/or dopamine secretion facilitation material, utilize itself or use known excipient in this field, can make it preparationization according to conventional methods, make liquid preparation or solid preparation.
Can enumerate liquor, syrup etc. as liquid preparation, solid preparation then has the oral administration form of powder, granule, chewable tablet, buccal tablet, Chewing gum etc.Improve the purpose of swallowing obstacle for reaching to greatest extent, compositions of the present invention is preferably the form of chewable tablet, buccal tablet, Chewing gum or the colloidal sol shape etc. that are applicable to mucosa in the oral cavity.
When making liquid preparation, can make water, glycerol, propylene glycol, simple syrup, ethanol, ethylene glycol, Polyethylene Glycol, Sorbitol etc. as excipient.
In addition, when making solid preparation, can use lactose for example, sucrose, glucose, corn starch, gelatin, starch, dextrin, calcium phosphate, calcium carbonate, synthetic or natural aluminium silicate, magnesium oxide, Aluminium Hydroxide, magnesium stearate, sodium bicarbonate, dry yeast etc. as excipient.
Moreover, in compositions of the present invention, can add the stabilizing agent of citric acid, phosphoric acid, malic acid or its esters etc. as required; The sweeting agent of the sweet taste material of the high sugariness of ス Network ラ ロ one ス (SucraloseR does not have Chinese translation), ア セ ス Le Off ア system カ リ ウ system (Chinese translation is not arranged) etc. or sucrose, fructose, Mel etc.; The antiseptic of alcohols, glycerol etc.; Common additive as diluent, buffer agent, fragrant agent and coloring agent etc. also can use.
The compositions of so making of the present invention, itself can be used as food or pharmaceuticals uses, also can be with raw material, intermediate or the end article of these compositionss as food or pharmaceuticals, make with improvement by mix or spraying etc. and to swallow food or the pharmaceuticals that obstacle is a purpose.
There is no particular limitation for the kind of food, for example can enumerate following example: livestock products processed goods (Petaso, roast meat, hamburger), aquatic products processing product (fish meat puree goods, fried tuna), agricultural production processed goods (vegetable, bean curd, the beans class, the soup class, the thing class salts down, Noodles, cake), milk product (cheese, yoghourt), egg products (mayonnaise, egg cake), rice processed goods (new year cake, sushi, fried rice with shrimps, the crisp rice fruitcake), sweets class (pudding, fruit jelly, snack), cold drink class (ice cream, sherbet), fruit processed goods (orange juice, strawberry jam), beverage (coffee, Lac Bovis seu Bubali, black tea, green tea, refreshment drink, drinks).
The obstacle of swallowing of the present invention improves with compositions when using as pharmaceuticals, is the adult of 60kg for body weight, and preferred one day dose for example is a capsaicin 4.5 * 10
-4～45 μ g, ACE inhibitory action material or P substance decomposition inhibitory action material are 0.03～1500mg, and dopamine secretion facilitation material then can use 1.5～1500mg.
In addition, when using as food, flavor and outward appearance that use amount is preferably not food exert an influence.
Yet these doses all will be according to the people's who takes compositions health status, throw to method and with various factors such as the combination of other preparation and change.
[embodiment]
Exemplify embodiment below and describe, these embodiment do not constitute any qualification to the present invention.
Embodiment:
With capsaicin (production of ALBS company), Lac regis apis enzyme analyte (production of ア ピ company) and theanine (sun chemical production) with excipient mix, briquetting, make the buccal tablet of bagel type.
In per 1 ingot, the content of capsaicin is 1.5 * 10
-1μ g, the content of Lac regis apis enzyme analyte and theanine respectively are 50mg.
This buccal tablet or placebo thrown for 3 times 1 middle of the month 1 give 58～93 years old people, cause test (with reference to non-patent literature 1), measure swallowing the time according to swallowing reflection.Test is carried out 3～5 times to after finishing continuously 3 times on the 1st throwing, calculates its meansigma methods as swallowing the time.
Its result is as shown in table 1.
Table 1
In above-mentioned test, the time of swallowing was normal at 3 seconds with in, then was judged to be more than 5 seconds and swallowed delay.According to this criterion, by the compositions of the present invention that capsaicin, Lac regis apis enzyme analyte and theanine constitute, can find out improvement significantly to the time of swallowing that postpones by picked-up.
And the result of picked-up placebo shows almost do not have effect to swallowing the time, also exists simultaneously and makes the tendency of swallowing time delay.
The invention effect
According to the present invention, utilize in Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 secretion facilitation material to cooperate angiotensins Invertase inhibitory action material or Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 decompose the inhibitory action material and/or the dopamine secretion is short Advance the composition that working substance forms, use separately with it and compare, because of their synergy Excellence can obtain better to improve to swallow the obstacle effect.
Claims (5)
1. the obstacle compositions is swallowed in an improvement, it is characterized in that:
In P material secretion facilitation material, cooperate ace inhibiting effect material or P substance decomposition inhibitory action material and/or dopamine secretion facilitation material to form,
Described P material secretion facilitation material is a capsaicin,
Described ace inhibiting effect material or P substance decomposition inhibitory action material are the acid breasts of her Mi Puli, cilazapril, captopril, alacepril, delapril hydrochloride, Lac regis apis and enzyme analyte thereof, wooden fish enzymic digestion thing, sardine enzymic digestion thing or Calpis
Dopamine secretion facilitation material is theanine or amantadine.
2. compositions as claimed in claim 1 is characterized in that: ace inhibiting effect material or P substance decomposition inhibitory action material are Lac regis apis and enzyme analyte thereof.
3. compositions as claimed in claim 1 is characterized in that: dopamine secretion facilitation material is a theanine.
4. as each described compositions in the claim 1～3, it is characterized in that: form is chewable tablet, buccal tablet, Chewing gum, colloidal sol shape.
5. food or the pharmaceuticals that obstacle is used are swallowed in an improvement that is made of each described compositions in the claim 1～4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-377267 | 2002-12-26 | ||
| JP2002377267 | 2002-12-26 | ||
| JP2002377267 | 2002-12-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1511542A CN1511542A (en) | 2004-07-14 |
| CN100431553C true CN100431553C (en) | 2008-11-12 |
Family
ID=32677390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031482597A Expired - Fee Related CN100431553C (en) | 2002-12-26 | 2003-06-30 | Composition for improving obstacle under pharynx |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPWO2004058301A1 (en) |
| CN (1) | CN100431553C (en) |
| AU (1) | AU2003296069A1 (en) |
| WO (1) | WO2004058301A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007125717A1 (en) * | 2006-04-24 | 2007-11-08 | Ajinomoto Co., Inc. | Agent for amelioration of dysphagia, and pharmaceutical or food composition comprising the same |
| BRPI0819342A2 (en) * | 2007-11-19 | 2015-05-19 | Nestec Sa | Orally administrable medicinal product or nutritional liquid, orally administrable liquid moisturizing product, modified texture food product, as well as the use of such products. |
| JP5828007B2 (en) * | 2011-12-21 | 2015-12-02 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | Topically-administered drugs for improving dysphagia |
| JP6122244B2 (en) * | 2012-02-29 | 2017-04-26 | ハウス食品グループ本社株式会社 | Composition having action of improving concentration persistence |
| JPWO2014199486A1 (en) * | 2013-06-13 | 2017-02-23 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | Drugs for improving dysphagia |
| US9974768B2 (en) | 2013-06-13 | 2018-05-22 | Meiji Seika Pharma Co., Ltd. | Pharmaceutical for improving dysphagia |
| CN108142940B (en) * | 2018-02-05 | 2021-05-14 | 中山大学附属第三医院（中山大学肝脏病医院） | Soft tablet for promoting swallowing and preparation method thereof |
| TW202038920A (en) * | 2018-12-27 | 2020-11-01 | 日商花王股份有限公司 | Effervescent oral solid preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1370468A (en) * | 2001-02-21 | 2002-09-25 | 焦柏忠 | Theanine product |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001086954A (en) * | 1999-09-20 | 2001-04-03 | Yakult Honsha Co Ltd | Health drink or food |
| JP4045401B2 (en) * | 2000-10-03 | 2008-02-13 | 株式会社山田養蜂場本社 | Degradation composition of royal jelly by proteolytic enzyme and food composition containing the same |
| JP2002133997A (en) * | 2000-10-20 | 2002-05-10 | Nissin Electric Co Ltd | Transformer protector |
-
2003
- 2003-06-30 CN CNB031482597A patent/CN100431553C/en not_active Expired - Fee Related
- 2003-12-24 AU AU2003296069A patent/AU2003296069A1/en not_active Abandoned
- 2003-12-24 WO PCT/JP2003/016525 patent/WO2004058301A1/en active Application Filing
- 2003-12-24 JP JP2004562896A patent/JPWO2004058301A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1370468A (en) * | 2001-02-21 | 2002-09-25 | 焦柏忠 | Theanine product |
Non-Patent Citations (2)
| Title |
|---|
| 辣椒素的药理与临床研究概况. 林倚雯等.广东药学2000，第10卷第5期. 2000 |
| 辣椒素的药理与临床研究概况. 林倚雯等.广东药学2000，第10卷第5期. 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004058301A1 (en) | 2004-07-15 |
| CN1511542A (en) | 2004-07-14 |
| AU2003296069A1 (en) | 2004-07-22 |
| JPWO2004058301A1 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2156751B1 (en) | Novel sweetener having sugar-like taste and production method and use of the same | |
| JP5876205B2 (en) | Method for improving deficiency of sweetness of D-sorbose in sweetener comprising D-sorbose and improving sweetness persistence | |
| CN101247801B (en) | Composition for prevention of increase in blood alcohol level | |
| EP1913943B1 (en) | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | |
| KR100900174B1 (en) | Agent for inhibiting rise in blood glucose level, agent for inhibiting body fat accumulation and edible material | |
| KR20180011006A (en) | Cereal bars with enhanced nutrients and suppressed elevation of blood sugar | |
| CN100431553C (en) | Composition for improving obstacle under pharynx | |
| JP5224680B2 (en) | Anti-fatigue | |
| JP2013233112A (en) | Food and drink | |
| JP2011254749A (en) | Mannose-containing composition | |
| JP2008088101A (en) | Antifatigue agent | |
| Antonik et al. | Characteristics of sweeteners used in foods and their effects on human health | |
| JP4716769B2 (en) | Method for producing antihypertensive agent | |
| JP2004269422A (en) | Immunoactivating composition | |
| US20070027214A1 (en) | Orally administered agent for improving skin condition | |
| JP4915959B2 (en) | Novel sweetener with sugar-like taste, production method and use thereof | |
| CN100411619C (en) | Composition for suppressing blood sugar ascending | |
| JP4851902B2 (en) | Body fat accumulation inhibitor | |
| US20070093554A1 (en) | Agent for improving feeling of cold | |
| JP2004000164A (en) | alpha-GLUCOSIDASE INHIBITOR AND COMPOSITION | |
| US20060258746A1 (en) | Oral medicament for improvement in going to sleep or waking | |
| CN100448374C (en) | Reducer of blood glucose level increase, reducer of body fat accumulation and food material | |
| US8993639B2 (en) | Compound and method for treatment of gastroesophageal reflux | |
| JP5943516B2 (en) | Sweetener for improving biological function comprising D-sorbose as an active ingredient | |
| CN104853760A (en) | Composition, drink food, visceral fat reducing agent and blood sugar level lowering agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081112 Termination date: 20210630 |